SMS Pharmaceuticals reports robust Q2FY24 operational performance
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Lupin enters into BTA with Lupin Manufacturing Solutions
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
The primary purpose of this collaboration is to bring the optimized protein into the Indian market
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Subscribe To Our Newsletter & Stay Updated